XSHE
000766
Market cap2.36bUSD
Jul 10, Last price
16.50CNY
1D
6.66%
1Q
-21.62%
Jan 2017
-6.04%
Name
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is a Chinese pharmaceutical firm actively involved in the full spectrum of drug development, from research and development to manufacturing and sales. Its therapeutic focus primarily encompasses key areas such as rheumatism, digestive health, oncology, and gynecology. The company boasts a comprehensive and diverse product portfolio. This includes a wide array of traditional Chinese medicines (TCMs), addressing conditions like gynecological issues, rheumatic and bone pain, urological disorders, detoxification needs, cardiovascular and cerebral health, digestive and respiratory ailments, diabetes, and pediatric concerns. Beyond TCMs, it also develops and markets anti-tumor drugs, both prescription and over-the-counter (OTC) medications, and conventional Western pharmaceuticals. These products are available in multiple dosage forms, including capsules, tablets, injections, and liquid preparations. Established in 1990, the company is headquartered in Tonghua, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||